全文获取类型
收费全文 | 90803篇 |
免费 | 5891篇 |
国内免费 | 701篇 |
专业分类
耳鼻咽喉 | 1507篇 |
儿科学 | 2363篇 |
妇产科学 | 1637篇 |
基础医学 | 11192篇 |
口腔科学 | 1690篇 |
临床医学 | 8615篇 |
内科学 | 19022篇 |
皮肤病学 | 1897篇 |
神经病学 | 8395篇 |
特种医学 | 3767篇 |
外国民族医学 | 5篇 |
外科学 | 14954篇 |
综合类 | 966篇 |
一般理论 | 99篇 |
预防医学 | 6622篇 |
眼科学 | 1911篇 |
药学 | 6201篇 |
中国医学 | 369篇 |
肿瘤学 | 6183篇 |
出版年
2023年 | 514篇 |
2022年 | 1060篇 |
2021年 | 2440篇 |
2020年 | 1305篇 |
2019年 | 2051篇 |
2018年 | 2404篇 |
2017年 | 1811篇 |
2016年 | 2099篇 |
2015年 | 2565篇 |
2014年 | 3506篇 |
2013年 | 4523篇 |
2012年 | 6765篇 |
2011年 | 6848篇 |
2010年 | 3939篇 |
2009年 | 3398篇 |
2008年 | 5709篇 |
2007年 | 5873篇 |
2006年 | 5561篇 |
2005年 | 5429篇 |
2004年 | 4960篇 |
2003年 | 4569篇 |
2002年 | 4222篇 |
2001年 | 805篇 |
2000年 | 732篇 |
1999年 | 811篇 |
1998年 | 863篇 |
1997年 | 770篇 |
1996年 | 664篇 |
1995年 | 580篇 |
1994年 | 560篇 |
1993年 | 477篇 |
1992年 | 432篇 |
1991年 | 449篇 |
1990年 | 354篇 |
1989年 | 342篇 |
1988年 | 351篇 |
1987年 | 311篇 |
1986年 | 311篇 |
1985年 | 393篇 |
1984年 | 460篇 |
1983年 | 394篇 |
1982年 | 546篇 |
1981年 | 507篇 |
1980年 | 474篇 |
1979年 | 237篇 |
1978年 | 307篇 |
1977年 | 298篇 |
1976年 | 226篇 |
1975年 | 235篇 |
1973年 | 199篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
2.
3.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
4.
5.
6.
7.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献8.
9.
10.
In this paper, we introduce a new type of troubled-cell indicator to improve
hybrid weighted essentially non-oscillatory (WENO) schemes for solving the hyperbolic conservation laws. The hybrid WENO schemes selectively adopt the high-order
linear upwind scheme or the WENO scheme to avoid the local characteristic decompositions and calculations of the nonlinear weights in smooth regions. Therefore,
they can reduce computational cost while maintaining non-oscillatory properties in
non-smooth regions. Reliable troubled-cell indicators are essential for efficient hybrid
WENO methods. Most of troubled-cell indicators require proper parameters to detect
discontinuities precisely, but it is very difficult to determine the parameters automatically. We develop a new troubled-cell indicator derived from the mean value theorem
that does not require any variable parameters. Additionally, we investigate the characteristics of indicator variable; one of the conserved properties or the entropy is considered as indicator variable. Detailed numerical tests for 1D and 2D Euler equations are
conducted to demonstrate the performance of the proposed indicator. The results with
the proposed troubled-cell indicator are in good agreement with pure WENO schemes.
Also the new indicator has advantages in the computational cost compared with the
other indicators. 相似文献